



Tamman Titoe Pharma Pvt Ltd
56-57, Sidco Pharmaceutical Complex,
Alathur-603 110, Tamilnadu.

QUALITY CONTROL DEPARTMENT
Certificate of Analysis of Finished Product
(Under Drug And Cosmetic Act. 1940 & The Rules There Under)

Report No: TT/ FG/513/24-25
Report Date: 23-01-2025

Name of the product :RANICAN Injection 2ml
Generic Name : Ranitidine Injection I.P 25mg/ml (Buffered)
Batch No. : RH501
Batch Size : 104000
Mfg. Date. : JAN-2025
Exp. Date. :DEC-2026
Quantity of Sample :100Nos
Date of Sampling :07-01-2025
Date of Commencement of analysis :07-01-2025
Date of Completion of analysis :22-01-2025

TEST NAME	SPECIFICATION	OBSERVATION
Description:	A clear, Pale yellow colour solution.	A clear, pale yellow colour Solution
Identification: A.(By IR)	The infrared absorption spectrum of sample is concordant with infrared absorption spectrum of Ranitidine Hydrochloride RS.	Complies to IP specification
B. In the Assay	The principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.	Complies to IP specification
pH(Buffered)	6.7 to 7.3	7.13
Extractable Volume	NLT- 2ml/Amp	2.1ml
Particulate matter	No visible particles	Complies
Bacterial endotoxins	NMT 7.0 EU/mg of Ranitidine.	LT 7.0 EU/mg
Sterility Test	To comply as per IP	Complies
Assay		
Each ml contains: Ranitidine Hydrochloride I.P Equivalent to Ranitidine 25mg	22.5 mg to 27.5 mg (90.0 % - 110%)	25.84mg (103.36%)

OBSERVATION: In the opinion of the undersigned the sample referred to above is of **Standard Quality/Not Standard Quality** as in the act and the rules made there under for the reason given below.

REMARKS : COMPLIES AS PER IP WITH RESPECT TO THE ABOVE TESTS ONLY CARRIEDOUT.

Analysed By: *L.H.S*
Date: 23/01/25

Checked By: *Sri*
Date: 23/01/2025

Person In Charge of Testing
Date: 23/01/25

